CTRI/2026/03/107152尚未招募2 期
A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Uncontrolled Moderate to Severe Asthma
Eli Lilly and Company (India) Pvt Ltd10 个研究点 分布在 1 个国家目标入组 531 人开始时间: 2026年5月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 531
- 试验地点
- 10
- 主要终点
- Annualized Asthma Exacerbation Rate Over 52 Weeks of Treatment
研究概览
简要总结
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma.
Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- Participant and Investigator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 75.00 Year(s)（—）
- 性别
- All
入选标准
- •Physician-diagnosed asthma who have received a physician-prescribed asthma controller medication for at least 12 months prior to screening visit.
- •Participants must have an asthma control questionnaire-6 (ACQ-6) score of equal to or more than 1.5 on 2 out of 3 visits before randomization.
- •History of 1 severe asthma exacerbation that led to systemic glucocorticoid treatment in the last 12 months prior to screening visit.
排除标准
- •Participants are excluded from the study if any of the following criteria apply:.
- •An established diagnosis of occupational asthma
- •Known pre-existing, clinically important lung condition other than asthma, including but not limited to:.
- •chronic respiratory infection.
- •bronchiectasis.
- •pulmonary fibrosis.
- •allergic bronchopulmonary aspergillosis.
- •chronic bronchitis.
- •eosinophilic granulomatosis with polyangiitis.
- •chronic obstructive pulmonary disease, and.
- •other mimics of asthma, that is, vocal cord dysfunction.
- •Have a current or recent acute, active infection. For at least 30 days before screening visit and up to the randomization visit.
结局指标
主要结局
Annualized Asthma Exacerbation Rate Over 52 Weeks of Treatment
时间窗: Baseline to Week 52
次要结局
- Change from Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1)(Baseline, Week 52)
- Change from Baseline in Patient Reported Health Outcomes(Baseline, Week 52)
- Time to First Exacerbation(Baseline to Week 52)
- Change from Baseline in Weekly Mean Rescue Medication Use(Baseline, Week 52)
- Pharmacokinetic (PK): Average Steady State Plasma Concentration (Cavg) of Brenipatide(Baseline up to Week 52)
- Percentage of Participants with Treatment-emergent Anti-Drug Antibody (ADAs)(Baseline to Week 52)
研究者
Dr Rahul Kapur
Eli Lilly and Company (India) Pvt. Ltd
研究点 (10)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or ObesityOverweightObesityNCT07476118Eli Lilly and Company150
招募中
2 期
A Study of Brenipatide in Adult Participants With SchizophreniaSchizophreniaNCT07410507Eli Lilly and Company450
尚未招募
2 期
A Study of Brenipatide in Adult Patients With SchizophreniaSchizophrenia,CTRI/2026/04/109019Eli Lilly and Company (India) Pvt Ltd450
尚未招募
2 期
A Study of Brenipatide in Adults with Bipolar DisorderBipolar disorder,CTRI/2026/03/106554Eli Lilly and Company (India) Pvt Ltd400
招募中
2 期
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)Bipolar DisorderNCT07286175Eli Lilly and Company400